CLL-IPI

The CLL-IPI was developed in the chemo-immunotherapy (CIT) era. While it remains a powerful prognostic tool, its ability to predict survival in the era of continuous BTK inhibitors (ibrutinib, acalabrutinib) and venetoclax is still evolving, though it remains highly discriminative for time-to-first-treatment.

Developed by an international consortium of CLL study groups (German, French, British, Mayo Clinic, etc.) to unify various disparate prognostic systems into a single validated index.